<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30014">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777217</url>
  </required_header>
  <id_info>
    <org_study_id>VESI-12J03</org_study_id>
    <nct_id>NCT01777217</nct_id>
  </id_info>
  <brief_title>VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate</brief_title>
  <official_title>A Pilot Study to Assess the Safety and Efficacy of Solifenacin (VESIcare) for Improving Urinary and Bladder Functions in Patients Undergoing Radiation Therapy of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Research Network</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Advanced Research Network</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective
      in treating over-active bladder symptoms during radiation therapy of the prostate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double blind placebo controlled flexible dose 12 week study. Following
      screening, subjects will receive their first dose of study medication following completion
      of AUASS questionnaire on the first day of radiation treatment (baseline) and will continue
      for twelve weeks. Subjects will be started on 5 mg of study medication.  The AUASS will be
      completed at baseline, weeks 4, 8 and 12. A 16 week visit conducted over a phone interview.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline to end of study measured by the American Urology Association Symptom Score Questionnaire (AUASS).</measure>
    <time_frame>baseline  and 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Over-Active Bladder</condition>
  <arm_group>
    <arm_group_label>solifenacin succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solifenacin succinate, 5mg or 10 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin succinate</intervention_name>
    <arm_group_label>solifenacin succinate</arm_group_label>
    <other_name>VESIcare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written
             Informed Consent and privacy language as per HIPAA Authorization for the USA test
             sites is obtained from subject or legally authorized representative prior to the
             initiation of  this study (including withdrawal of prohibited medication, if
             applicable)

          2. Subject must be an ambulatory male at least 18 years of age.

          3. Subject has been diagnosed with prostate carcinoma and has elected to undergo
             external beam radiation therapy.

          4. Subject is willing to complete the American Urology Association Symptom Score (AUASS)
             Questionnaire.

        Exclusion Criteria:

          1. Subject has undergone a prostatectomy

          2. Subject exhibits symptoms of urinary tract infection.

          3. Subject exhibits severe neurologic damage or has undergone prostatectomy.

          4. Subject diagnosed with OAB and is being treated with medication for alleviation of
             OAB symptoms within 12 months prior to the Screening Visit.

          5. Subject has evidence of uncontrolled narrow angle glaucoma, urinary or gastric
             retention, neurogenic bladder; prostatitis, or persistent UTI.

          6. Subject exhibits hypersensitivity to Solifenacin succinate, any ingredients, or other
             anticholinergic agents.

          7. Subject has undergone treatment with any investigational drug within 30 days prior to
             screening procedure.

          8. Subject has exhibited history of diagnosed gastrointestinal obstructive disease.

          9. Subjects with co-morbid lower urinary tract symptoms (LUTS).

         10. Subjects exhibiting clinically significant bladder outflow obstruction (BOO).

         11. In the opinion of the Study Investigator, the patient has exhibited prior to the
             screening or Baseline visit, a clinically significant disease or medical condition
             that would exclude the subject from participating in the study.

         12. Subjects who have received prior pelvic radiation.

         13. Subjects with history of severe hepatic impairment.

         14. Subjects with history of Congenital or Acquired QT prolongation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Mehta, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Century Cancer Centers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rima King, BS, CCRP</last_name>
    <phone>832-681-8740</phone>
    <email>rking@advancedresearchnetwork.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Century Cancer Center</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Cruz, RN</last_name>
      <phone>720-214-6500</phone>
    </contact>
    <investigator>
      <last_name>Barry Blyton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Century Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Starr Walker</last_name>
      <phone>713-630-8181</phone>
    </contact>
    <contact_backup>
      <last_name>Rokisha Howard</last_name>
      <phone>713-630-8181</phone>
    </contact_backup>
    <investigator>
      <last_name>Sanjay Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 6, 2013</lastchanged_date>
  <firstreceived_date>January 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urination Disorder</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>Prostate Cancer Radiation</keyword>
  <keyword>Vesicare</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
